MG
MRNA icon

Marex Group’s Moderna MRNA Stock Holding History

Marex Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.2M Buy
88,575
+24,953
+39% +$1.29M 0.03% 221
2026
Q1 		$3.23M Buy
63,622
+35,104
+123% +$1.64M 0.02% 266
2025
Q4 		$841K Sell
28,518
-207,837
-88% -$5.65M 0.01% 436
2025
Q3 		$6.11M Buy
236,355
+223,356
+1,718% +$6.23M 0.04% 176
2025
Q2 		$359K Sell
12,999
-116,901
-90% -$3.08M ﹤0.01% 416
2025
Q1 		$3.68M Buy
129,900
+43,000
+49% +$1.53M 0.07% 128
2024
Q4 		$3.61M Buy
86,900
+67,635
+351% +$3.23M 0.06% 113
2024
Q3 		$1.29M Buy
19,265
+3,920
+26% +$360K 0.03% 195
2024
Q2 		$1.82M Sell
15,345
-1,250
-8% -$158K 0.05% 168
2024
Q1 		$1.77M Buy
16,595
+2,305
+16% +$232K 0.06% 143
2023
Q4 		$1.42M Buy
14,290
+5,825
+69% +$490K 0.06% 184
2023
Q3 		$874K Buy
+8,465
New +$944K 0.12% 80
2023
Q2 		– Sell
-6,535
Closed -$1M – 283
2023
Q1 		$1M Sell
6,535
-20,451
-76% -$3.37M 0.13% 107
2022
Q4 		$4.83M Buy
+26,986
New +$4.41M 0.69% 29

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Marex Group's MRNA Position: Q2 2026 in Review

Marex Group increased its Moderna (MRNA) stake by 39% in Q2 2026, buying an estimated $1.29M and bringing the position to 88,575 shares worth $6.2M. The position accounts for 0.03% of the portfolio, ranked #221.

Marex Group first reported a position in MRNA in Q4 2022 and has held it in 14 quarters since. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Marex Group held 88,575 shares of Moderna worth $6.2M as of Q2 2026.
  • Marex Group bought 24,953 Moderna shares in Q2 2026, an estimated $1.29M.
  • Moderna made up 0.03% of Marex Group's portfolio in Q2 2026, its #221 holding.
  • Marex Group first reported a position in Moderna in Q4 2022 and has held it in 14 quarters since.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.